Venus Remedies Ltd
Venus Remedies Ltd (VENUSREM) last reported results for the quarter ended Jun 2026, with sales of ₹179 crore and net profit of ₹23 crore. The stock last traded at ₹1,715, a market capitalisation of ₹2,293 crore, on a P/E of 19.7. Over the past 52 weeks the stock has ranged between ₹432 and ₹2,044. Figures are as of 6 Oct 2026 and are not real time.
Venus Remedies Ltd share price and key metrics
- Current price
- ₹1,715
- Market cap
- ₹2,293 cr
- Stock P/E
- 19.7
- Book value
- ₹497
- ROE
- 15.6%
- ROCE
- 20.7%
- Dividend yield
- 0.57%
- 52w high / low
- 2044/432
Metrics as of 6 Oct 2026. Not real time.
Track Venus Remedies Ltd
Cruxal reads every Venus Remedies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Venus Remedies Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 7%
- 3 Years
- 12%
- TTM
- 20%
- 10 Years
- 50%
- 5 Years
- 20%
- 3 Years
- 53%
- TTM
- 149%
- 10 Years
- 30%
- 5 Years
- 32%
- 3 Years
- 97%
- 1 Year
- 278%
- 10 Years
- 4%
- 5 Years
- 9%
- 3 Years
- 10%
- Last Year
- 16%
Venus Remedies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹179 cr, up 30.7% from ₹137 cr a year earlier. Net profit was ₹23 cr, up 130.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 |
| Expenses | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 |
| Operating profit | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 |
| OPM % | 4.5% | 10% | 15% | 11% | 16% | 21% | 24% | 19% |
| Other income | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 |
| Profit before tax | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 |
| Tax % | 61% | 21% | 32% | 24% | 24% | 24% | 23% | 24% |
| Net profit | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 |
| EPS (₹) | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.54 | 17.18 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Venus Remedies Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 400 | 372 | 322 | 335 | 544 | 597 | 552 | 596 | 645 | 766 | 811 |
| Operating profit | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 69 | 147 | 166 |
| OPM % | 13% | 11% | 10% | 12% | 10% | 10% | 11% | 10% | 11% | 19% | 20% |
| Net profit | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 103 | 116 |
| EPS (₹) | -13.84 | -24.87 | -23.15 | -8.10 | 50.05 | 30.46 | 19.88 | 21.31 | 33.90 | 76.90 | 86.92 |
TTM is the trailing twelve months to the most recent quarter.
Venus Remedies Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 376 | 350 | 320 | 311 | 388 | 427 | 447 | 474 | 548 | 650 |
| Borrowings | 312 | 307 | 298 | 220 | 51 | 43 | 42 | 41 | 2 | 12 |
| Other liabilities | 65 | 82 | 102 | 100 | 104 | 97 | 98 | 98 | 153 | 178 |
| Total liabilities | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
| Fixed assets | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 | 232 |
| CWIP | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 | 51 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 | 238 |
| Other assets | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 376 | 333 |
| Total assets | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
As reported by the company. Total assets equal total liabilities by construction.
Venus Remedies Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 | 156 |
| Cash from investing | -18 | 8 | -11 | -5 | 57 | -17 | -58 | -8 | -77 | -185 |
| Cash from financing | -44 | -39 | -35 | -73 | -162 | -9 | -1 | -1 | -1 | -3 |
| Net cash flow | -4 | 0 | -1 | -0 | 27 | 14 | -22 | 28 | 9 | -32 |
| Free cash flow | 41 | 19 | 35 | 70 | 132 | 41 | 29 | 24 | 69 | 118 |
| CFO / operating profit | 116% | 79% | 139% | 190% | 245% | 66% | 61% | 89% | 148% | 129% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Venus Remedies Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 2% | 1% | 1% | 2% | 8% | 8% | 8% | 9% | 11% | 21% |
| Debtor days | 43 | 46 | 43 | 33 | 21 | 24 | 51 | 49 | 64 | 49 |
| Inventory days | 226 | 246 | 286 | 296 | 129 | 118 | 132 | 125 | 97 | 122 |
| Days payable | 48 | 52 | 72 | 77 | 76 | 47 | 56 | 55 | 89 | 107 |
| Cash conversion cycle | 221 | 240 | 257 | 252 | 74 | 95 | 127 | 120 | 72 | 64 |
| Working capital days | 54 | 25 | -1 | 73 | 71 | 82 | 109 | 118 | 86 | 62 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Venus Remedies Ltd shareholding pattern
Promoters held 41.76% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.92% and DIIs 0.89%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| FIIs | 1.18% | 1.11% | 1.34% | 2.25% | 1.86% | 2.25% | 2.80% | 2.92% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.11% | 0.75% | 1.03% | 1.20% | 0.89% |
| Public | 57.06% | 57.13% | 56.90% | 55.89% | 55.62% | 54.95% | 54.24% | 54.44% |
| No. of shareholders | 19,557 | 19,771 | 19,982 | 19,307 | 17,725 | 18,606 | 18,403 | 21,905 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Venus Remedies Ltd corporate filings
- Compliance under Reg 74(5) of SEBI (DP) regulations.Company Updatelow impact
- Venus Remedies Ltd updates CIN, no financial impact reportedCompany Updatelow impact
Cruxal's analysis: Venus Remedies Ltd has filed an intimation regarding a change in its Company…
Read the full analysis - Closure of trading window.Insider Trading / SASTlow impact
- Venus Remedies Ltd publishes shareholder notice regarding transfer of physical sharesCompany Updatelow impact
Cruxal's analysis: Venus Remedies Ltd has issued a newspaper publication as part of its regulatory…
Read the full analysis - Venus Remedies Ltd publishes newspaper notice regarding transfer of physical sharesCompany Updatelow impact
Cruxal's analysis: Venus Remedies Ltd has issued a mandatory newspaper publication to inform shareholders…
Read the full analysis - Venus Remedies Ltd issues shareholder awareness notice regarding physical share transfersCompany Updatelow impact
Cruxal's analysis: Venus Remedies Ltd has released a social media-based communication to create awareness…
Read the full analysis - Venus Remedies Limited concludes 37th AGM; shareholders approve all 12 resolutions including final dividend of INR 10 per shareAGM/EGMlow impact
Cruxal's analysis: Venus Remedies Limited has successfully concluded its 37th Annual General Meeting held on…
Read the full analysis - Venus Remedies Ltd announces amendments to Memorandum and Articles of AssociationCompany Updatelow impact
Cruxal's analysis: Venus Remedies Ltd has filed an announcement regarding amendments to its Memorandum and…
Read the full analysis - Venus Remedies Limited concludes 37th AGM; shareholders approve all resolutions including dividend and board re-appointmentsAGM/EGMlow impact
Cruxal's analysis: Venus Remedies Limited has successfully concluded its 37th Annual General Meeting held on…
Read the full analysis - Venus Remedies Limited Announces Board Appointments and Re-appointments Following 37th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Venus Remedies Limited has formalized the appointment and re-appointment of key…
Read the full analysis - Venus Remedies Limited concludes 37th AGM; declares final dividend of INR 10 per shareAGM/EGMlow impact
Cruxal's analysis: Venus Remedies Limited has successfully concluded its 37th Annual General Meeting, where…
Read the full analysis - Venus Remedies Ltd announces routine newspaper publication under Regulation 30 of LODRCompany Updatelow impact
Cruxal's analysis: Venus Remedies Ltd has made a routine announcement on 2026-08-04 regarding a newspaper…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.